



PCT / IB 03 / 04056
2.7.10.03
1.8 MAR 2003
INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House

Cardiff Road

Newport REC'D 10 NOV 2003

South Wales

NP10 8QQ

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

R. Mahoney

Dated

10 October 2003

BEST AVAILABLE COPY

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

★ 20 SEP 2002 ★

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference PWC/P341130B

22SEP02 E749994-15 000056

P01/7700 0.00-0221940.0

2. Patent application number
(The Patent Office will fill in this part)

0221940.0

3. Full name, address and postcode of the or of each applicant (underline all surnames)

BiOPRODUCTION
Athena Biodetection Aps
Solvgade 14 A
DK-1307 Copenhagen K
Denmark

20 SEP 2002

Patents ADP number (if you know it)

8468175001

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

Antibody and Screening Method

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

~~Kilburn & Strod~~
~~20 Red Lion Street~~
~~London~~
~~WC1R 4PL~~

D Young & Co
21 New Fetter Lane
London
EC4A 1DA

see 75(77)
8/9/03

Patents ADP number (if you know it)

~~125001~~

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 14

Claim(s) 4

Abstract

Drawing(s) 4

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr Paul W. Chapman
Tel: 020 7539 4200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Antibody and screening method.

The present invention relates to a method of producing antibodies in transgenic plants and a method of screening such antibodies.

5 AIDS is caused by the human immunodeficiency virus-1 (HIV-1) and is one of the major infectious diseases affecting more than 40 million people worldwide (UNAIDS estimation, 2001). Both industrialized world and low-income countries are concerned. Despite the efforts undertaken by researchers during
10 the last 20 years, only few treatments are available to date. Moreover, the cost of the highly active anti-retroviral therapy is prohibitive in non-industrialized countries. The HIV-1 virus employs a multitude of schemes to generate variants, such as accumulation of base substitutions, insertions and/or deletions within its genome, addition and/or loss of glycosylation sites in the envelope
15 protein, as well as recombination. This ability to mutate in infected individuals is one of the main reasons why the virus escapes natural defences before infected patients become immuno-compromised.

The molecular structure of human antibodies that are specific for HIV-1 are of
20 major interest as AIDS research progresses toward passive immunotherapeutics in the maintenance and prevention of infection. In recent years a number of human, HIV-specific hybridomas and Epstein-Barr virus (EBV)-transformed B cell lines, as well as a combinatorial library, have been developed and characterized at the molecular level. These sources have provided valuable
25 information on the immunoglobulin heavy- and light-chain variable-region gene usage and the extent and appearance of somatic mutation in a disease where the immune system is under constant stimulation over a long period of time.

Despite major advances in *in vitro* synthesis of monoclonal antibodies (mAB), such as the hybridoma method, production of purified antibody preparations in commercially acceptable quantities remains a challenge. In particular, existing commercial methods require expensive colonies of laboratory animals or large-scale cell culture facilities. Moreover, hybridomas involve the use of EBV, murine myeloma fusion partners, and may also entail bovine component during transformation and adaptation to serum-free media. Therefore, purification of recombinant antibodies from animals or from animal cell culture relies on the ability to remove potentially contagious agents, especially in light of the recent bovine epidemic of spongiform encephalopathy (BSE) and the related human disease entity, variant Creutzfeld-Jacob disease (Will et al., 1996). Additionally, such purification requires the preservation of the conformational integrity and biological activity of the mAB.

Since the early description of mAB (Kohler and Milstein 1975) there has been great interest in their use in human serotherapy. However, several problems have hindered their adoption, including the antiglobulin response, which is observed with antibodies produced in rodents in prolonged human therapy. This antiglobulin response is due to sequence divergence between human and rodent antibody molecules (Kabat et al., 1991), such that injection of rodent mAB into patients usually elicits an antiglobulin response at 8-12 days with a peak at 20-30 days (Isaacs et al., 1990). The antiglobulin response therefore precludes treatment beyond 10 days, and the rapid onset of a secondary response prevents further treatment.

As alternative to rodents, antibodies could be supplied by immunized volunteers. However, deliberate immunization of a hitherto non-immunized individual presents both practical and ethical problems (Power et al., 1995).

Protein engineering using various recombinant DNA technologies offers potential solutions to some of these problems. One such approach is the production of antibodies in plants (Richter et al., 2000, Belanger et al., 2000; De Jaeger et al., 2000). Transgenic plants represent a cheap and safe alternative to cell culture systems for producing human proteins. Protein processing is well conserved among plant and mammalian cells. For example, both mammalian and plant proteins undergo post translational modifications such as glycosylation, complex folding or multimeric assembly. Since transgenic plants have been shown to express correctly folded, full-length antibody (Hiatt et al., 1989), the opportunity offered for large-scale production of cheap recombinant antibodies or immunoglobulin-derived fragments lead to potential diagnostic and therapeutic applications (Giddings et al., 2000; Fisher & Emans, 2001). Therapeutical immunoglobulins produced in transgenic plants have so far been mostly targeted against mucosa-associated diseases (Ma et al., 1998; Verch et al., 1998; Zeitlin et al., 1998). Recently, production of an antibody targeted against an antigen present in the blood stream was reported (Bouquin et al., 2002). Potential advantages of plant-derived antibodies, referred here as "plantibodies", include

- (i) The capacity for producing large amounts of the desired antibody.
- (ii) Plant cells, in contrast to human cells, are not natural hosts for human pathogens; i.e. the risk of contamination with vira or prions from plants is essentially nonexistent
- (iii) Transgenic plants expressing the gene of interest are easily generated from various species using well-established techniques. This is in contrast to animal/human cell cultures that require fusion to myeloma partners to immortalize valuable cell lines during creation of hybridomas.

- (iv) Transgenic plants can be stored as seeds, an extremely cheap and stable method of storage.

5 The present invention provides a solution to the problems associated with the prior art by generating human antibody libraries, targeted against infectious agents, in transgenic plants. Specific examples include antibodies targeted against HIV-1 and A- or B- influenza viruses.

10 Thus in the first aspect the present invention provides a nucleic acid construct comprising:

- (i) a sequence encoding an immunoglobulin heavy chain,
- (ii) a sequence encoding an immunoglobulin light chain, and
- (iii) a dual promoter,

15 wherein both said sequences contain a multivariable region, the expression of both said sequences are controlled by the dual promoter, and said dual promoter is capable of controlling expression in a plant.

The nucleic acid can be either DNA or RNA.

20 An "Immunoglobulin" is an antibody. Antibodies are composed of constant regions (Fc) that determine the effector function of the antibody and the antigen binding domains (Fab) which comprise a unique set of complementarity determining regions (CDRs). The role of antibodies is to bind to antigens, thereby making them more visible to the immune system. Antigen-antibody (Ag-Ab) complexes can bind to Fc receptor on phagocytic cells to allow
25 efficient digestion of harmful pathogens. Fc receptor internalisation also allows efficient antigen presentation to stimulate T cell responses. Previous studies have shown that Fc receptor internalisation of Ag-Ab complexes is 1,000 fold more efficient than pinocytosis for stimulation of helper T cell

responses. More recently, it has been shown that Fc receptor internalisation of antigen-antibody complexes by dendritic cells also allows more efficient processing of antigen into class I and class II presentation pathways to allow stimulation of not only helper but also cytotoxic T cell responses (Regnault *et al.*, (1999) *J exp Med.* 189: 371-380). Furthermore, Fc receptor internalisation activates dendritic cells to express co-stimulatory molecules essential for priming naïve responses. Fc receptor internalisation is a consequence of receptor cross linking by antigen/antibody complexes and previous studies have shown that Ab alone cannot mediate this effect.

The term "immunoglobulin" also covers any polypeptide, protein or peptide having a binding domain which is, or is homologous to, an antibody binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced. Examples of antibodies are the immunoglobulin isotypes and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and diabodies.

It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CH1 domains; (ii) the Fd fragment consisting of the VH and CH1 domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. *et al.*, *Nature* 341:544-546 (1989)) which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')₂ fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv), wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird *et al.*, *Science* 242:423-426 (1988); Huston *et al.*, *PNAS USA* 85:5879-5883 (1988)); (viii) bispecific single

chain Fv dimers (PCT/US92/09965) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion (WO94/13804; P. Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993)).

5 Each immunoglobulin molecule is comprised of four polypeptide chains, two identical light chains and two identical heavy chains, held together by interchain disulphide bonds. Each polypeptide chain contains a constant domain and a variable domain. The variable domain contains three hypervariable sequences, forming the "multivariable region" which is involved
10 in the recognition of the antigen. The coding sequence of the multivariable regions can be altered by exchanging, inserting or deleting one or more nucleotides as compared to the original said immunoglobulin sequence. This provides a large number of combinations in the variable domain, so producing antibodies which can bind to a large number of antigens. The dual promoter is
15 preferably *mas1* '2' from the *A. tumefaciens* Ti plasmid.

The nucleic acid sequence can further comprise any one or more of terminators, enhancers, promoters, or sequences to enable cloning and/or purification of the protein. These sequences include marker genes, poly
20 restriction sites, and sequences that encode protein tags, such as FLAG, biotin, or polyhistidine tags. "Marker genes" include genes such as antibiotic resistance or sensitivity genes which may be used in identifying clones containing nucleic acid of interest, as is well known in the art.

25 In a second aspect the present invention provides a vector which contains the nucleic acid sequence defined aboved. This vector is, in one preferred embodiment C2200-DP-HK-LC.

In another aspect the present invention provides a host plant cell containing a nucleic acid construct, or vector as defined herein. A whole plant can be regenerated from the single transformed plant cell by procedures well known in the art. The invention also provides for propagating material or a seed comprising a cell. The invention also relates to any plant or part thereof including propagating material or a seed derived from any aspect of the invention.

The invention also provides a method of creating a library in a plant in which human antibodies can be expressed and arrayed against a panel of antigen targets. Such a technology may be desirable, as a major survival strategy of viruses such as HIV is to undergo genome mutations that lead to the modification of viral proteins. As a consequence, antibodies produced by infected patients become inefficient and the virus overcomes the immune response. By establishing individual plant lines expressing single or multiple antibodies directed against different viral antigen variants it will be possible to pool several lines to allow rapid selection of appropriate antibodies targeted against a given antigen using a grid-based screen. As an example a library of 10,000 different combinations could be screened such that the first layer of pooling 10 plants would reduce the pool number to 1000, the second layer to 100 and the third one to 10 pools. Therefore each selection step would discard 90% of non-functional combinations. Based on this technique, from a library containing 10,000 combinations, only three selection steps would be sufficient to identify the pool of 10 plants that contains the specific antibody to be used for serotherapy or diagnostic.

Thus in a further aspect the present invention provides A method for selecting plants producing antibodies that bind to a specific protein, or fragment thereof, comprising the following steps:

- (a) purify recombinant antibodies from a pool of plants expressing said antibodies;
- (b) assay said antibodies to determine whether any bind to the specific protein or fragment thereof;
- (c) and if the results of step (b) are positive, repeating steps (a) and (b) with the pool of plants sub divided into smaller groups; and
- (d) repeating steps (a) to (c) until the plant producing the antibody that binds the specific protein or fragment thereof is identified.

(e)

In one preferred embodiment antibodies are assayed by means of ELISA to identify those antibodies that bind to the specific protein or fragment thereof. The specific protein is preferably a viral protein, more preferably an HIV protein, most preferably an HIV-1 envelope protein.

Hereinafter, the present invention will be described in detail by way of illustrative, but not restrictive, examples and with reference to the following figures:

Figure 1 Construction of a human antibody expression cassette targeted against different variants of the V3 loop of the HIV-1 virus envelope protein

Figure 2. Cloning of human antibody expression cassette into plasmid, capable of expressing antibody in plants.

Figure 3 Selection of transgenic lines by means of a grid based screening system

Figure 4 Overview of pooling method of screening system.

Example 1.

Sequence alignment of human antibody light chain cDNAs targeted against the hypervariable V3 loop of the HIV-1 virus gp120 envelope protein.

- 5 Sequences were retrieved from the publicly available databases and aligned using a sequence alignment program. The sequence alignment of different human antibody light chain cDNAs targeted against the hypervariable V3 loop of HIV-1 was carried out. Alignment shows that the immunoglobulin chains exhibit well conserved sequences within the variable domains of antibodies.
- 10 However, some 25 amino acid residues appear to be less conserved. This result suggests that these sequence differences reflect mutational variants of the viral protein.

Example 2. Design of a human antibody expression cassette to be used for inserting the 25 variable motifs.

- 15 A human antibody expression cassette containing both heavy chain (HC) and light chain (LC) genes coding for mABs targeted against the V3 loop of the HIV-1 virus gp120 envelope protein is described hereafter. Degenerated overlapping oligonucleotides representing different immunoglobulin variable
- 20 heavy (VH) and variable light (VL) chain combinations were designed (Table 1). Each immunoglobulin variable chain is Polymerase Chain Reaction (PCR)-assembled independently by virtue of the complementarity between the degenerate primers used (Figure 1). A second round of PCR is performed so that the VH and VL PCR fragments are fused to the *mas1'2'* dual promoter
- 25 (DP) from the *A. tumefaciens* Ti plasmid (Velten et al., 1984). This second round of PCR is performed in presence of DP DNA and the newly synthesized VH and VL PCR fragments, whose extremities close to the immunoglobulin ATG translational start codons are overlapping the DP fragment. The immunoglobulin constant heavy (CH) and constant light (CL) chain fragments

are PCR-amplified independently in presence of CH and CL DNA template using a combination of forward and reverse oligonucleotides. The CH and CL PCR reverse primers were designed so that their 5' regions respectively contain the *attB1* and *attB2* recombination sites, as well as unique restriction enzyme (RE) sites that can be used for sub-cloning the cassette. Using a PCR-based strategy, the CH and CL chain fragments are fused to the PCR fragment obtained in the second round of PCR by using CH and CL DNA templates whose upstream extremities are overlapping with the VH-DP-VL fragment. The subsequent cassette, here designed DP-HC-LC, containing HC and LC that are transcriptionally regulated by the DP promoter, and flanked by the unique RE sites and the *attB* recombination signals, is subsequently recombined or cloned into a plasmid (C2200-GATEWAY) that contains the *attB* sequences and two plant transcriptional terminators (Figure 2). Additionally, this plasmid contains all features required for bacterial selection and plant transformation. The resulting plasmid, designated here C2200-DP-HC-LC is mobilized into *E. coli* bacteria using standard procedures to generate a library containing more than 10⁶ independent clones.

Example 3.

Transformation and generation of 25 *Arabidopsis thaliana* lines expressing human antibodies targeted against the V3 loop of the HIV-1 virus envelope protein

For transformation of *Arabidopsis thaliana*, plants are grown to flowering stage under standard greenhouse conditions, 24°C day/20°C night. Plants are typically planted 20 per 64 cm² pot in moistened potting soil. To obtain more floral buds per plant, inflorescences are clipped after most plants have formed primary bolts to promote synchronized emergence of multiple secondary inflorescences. New inflorescences are allowed to grow for 8 days. Transgene constructs are mobilized into *Agrobacterium tumefaciens* by electroporation

according to Shen and Forde (1989) prior to plant transformation by either vacuum infiltration (Bechtold and Pelletier, 1998) or by the floral dip method (Clough and Bent, 1998). After transformation, plants are allowed to self-pollinate, thereafter resulting T₁-generation seedlings are selected on
5 Murashige & Skoog Basal medium plates supplemented with 50 mg/l kanamycin, followed by transfer to soil. Approximately 20 lines for each construct are analyzed further.

Primary analyzes are conducted on transgenic line to confirm expression of the
10 immunoglobulin chains, correct folding of plantibodies, as well as functionality assays to evaluate binding to the antigens targets. These include RT-PCR and northern blot (to assess transgene expression), western blot under reducing and non-reducing conditions (to assess transgenic proteins production and correct immunoglobulin chains assembly). Antigen-antibody interaction assays are
15 performed by means of enzyme-linked immunosorbent assay (ELISA) using HIV-1 envelope protein-coated immunoplates, followed by incubation with transgenic plant extract, and detection of the transgenic antibody using an alkaline phosphatase-conjugated secondary antibody.

20 **Example 4. Selection of transgenic lines by means of a grid-based screening procedure**

Transgenic plants expressing human antibodies targeted against the V3 loop of the HIV-1 virus envelope protein are allowed to self-pollinate. T₂-generation progeny seeds are mixed in pools of 1000 then plated on Murashige & Skoog
25 Basal medium plates supplemented with 50 mg/l kanamycin. Recombinant antibodies are purified from each pool using standard techniques then each pool of antibodies is assayed for interaction with V3 loop variants of the HIV-1 virus envelope by means of sandwich ELISA assays. V3 loop variants are coated on 96-well flat-bottom plastic plates (Maxysorp, Nunc, Denmark) in

0.05 M carbonate / bicarbonate buffer, pH 9.6. (Figure 3) Pools producing a positive results were subdivided into smaller pools and the process repeated to identify plants expressing the desired antibodies. (Figure 4)

5 *References*

Belanger H, Fleish N, Cox S, Bartman G, Deka D, Trudel M, Koprowski H, Yusibov V. Human respiratory syncytial virus vaccine antigen produced in plants.

10 FASEB J. 2000 Nov;14(14):2323-2328.

Bouquin T, Thomsen M, Nielsen LK, Green TH, Mundy J and Dziegiel MH (2002) Human anti-Rhesus D IgG1 antibody produced in transgenic plants. *Transgenic Res* 11: 115-122.

15

Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. *Transgenic Res*. 2000 Jun;9(3):187-94.

20 De Jaeger G, De Wilde C, Eeckhout D, Fiers E, Depicker A. The plantibody approach: expression of antibody genes in plants to modulate plant metabolism or to obtain pathogen resistance. *Plant Mol Biol*. 2000 Jul;43(4):419-28.

Fischer R and Emans N (2000) Molecular farming of pharmaceutical proteins. *Transgenic Res* 9: 279-299.

25

Giddings G, Allison G, Brooks D and Carter A (2000) Transgenic plants as factories for biopharmaceuticals. *Nat Biotechnol* 18: 1151-1155.

Hiatt A, Cafferkey R and Bowdish K (1989) Production of antibodies in transgenic plants. *Nature* 342: 76–78.

5 Isaacs JD. The antiglobulin response to therapeutic antibodies. *Seminars in Immunology* 1990; 2: 449-456.

Kabat EA, Wu TT, Perry HM, et al. Sequences of proteins of immunological interest. US Department of Health and Human Services, U.S. Government Printing Office, 1991.

10

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975; 256: 495-497.

15

Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L et al. (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. *Nat Med* 4: 601–606.

20

Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. Production of hepatitis B surface antigen in transgenic plants for oral immunization. *Nat Biotechnol*. 2000 Nov;18(11):1167-1171.

25

Verch T, Yusibov V and Koprowski H (1998) Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. *J Immunol Methods* 220: 69–75.

Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM et al. (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. *Nat Biotechnol* 16: 1361–1364.

Table 1

Oligonucleotide	Sequence (5' → 3')	Comment
DP1	<u>Ggagctgtgtcatcagatgcgggaatgcacacigtacgtgtgtgtctaccagaagaggagat</u> <u>gatacagctccatcccatcttaagatccctttatatigagattttcaaatcagtgggc</u>	Overlapping with VL-1 (bold) Murine leader (underlined) Start codon (bold & underlined) DP-specific (normal font)
DP2	<u>Acgcctccccagactgtaccagctggaccctggggaatgcacacigtacgtgtgtgtctaccaa</u> <u>gaagaggatgatacagctccatccatccatcgatttgggtatcgagattggttatgaaat</u>	Overlapping with VH-1 (bold) Murine leader (underlined) Start codon (bold & underlined) DP-specific (normal font)
VH-1		
VH-2		
VH-3		
VL-1	<u>Gacatcgtgatgacacagtctccagacacccctgtcttctccaggaggaaagagccacct</u> <u>ctcctgcaggggccagtcagagtgttagcagcggctacttagcctgtgtaccagcagaaaacctgg</u> <u>ccaggctcccaggctcctctctat</u>	Overlapping with DP-1 (bold) Overlapping with VL-2 (underlined)
VL-2	<u>Ctgacagtaatacactgcaaaatcttcaggctccagctcgtgtgatgtgagagtgagtctgt</u> <u>cccagaccactgccactgaacctgtgtgtggatgccagtgggccctgtgtggagccaccatagat</u> <u>gagagcctggagagccctggccagg</u>	Overlapping with VL-3 (bold) Overlapping with VL-1 (underlined)
VL-3	<u>Cctgaagattttgcagtgattactgtcagcagatgatactcaccgccgtggacgttgggc</u> <u>caaggggaccaagggtggaaatcaaacg</u>	Overlapping with VL-2 (bold)

Claims

1. A nucleic acid construct comprising:

- (i) a sequence encoding an immunoglobulin heavy chain,
- (ii) a sequence encoding an immunoglobulin light chain, and
- (iii) a dual promoter,

wherein both said sequences contain a multivariable region, the expression of both said sequences are controlled by the dual promoter, and said dual promoter is capable of controlling expression in a plant.

2. The nucleic acid construct as claimed in claim 1, wherein the coding sequence of said multivariable regions have been altered by exchanging, inserting or deleting one or more nucleotides as compared to the original said immunoglobulin sequence.

3. The nucleic acid construct as claimed in claim 1 or claim 2, wherein said dual promoter is *mas1* '2' from the *A. tumefaciens* Ti plasmid.

4. The nucleic acid construct as claimed in any one of claims 1 to 3 further comprising any one or more selected from terminators, enhancers, promoters, or sequences to enable cloning and/or purification of the protein.

5. A vector containing the nucleic acid construct of any one of claims 1 to 4.

6. The vector as claimed in claim 5 wherein said vector is C2200-DP-HK-LC.

7. A plant cell comprising nucleic acid construct as defined in any one of claims 1 to 4 or a vector as claimed in claim 5 or claim 6.

5 8. A whole plant, or part thereof comprising a plant cell as defined in claim 7.

9. The seed, and/or propagating material of a plant as claimed in claim 8.

10 10. A method for the production of populations of antibodies comprising construction of a nucleic acid construct of claims 1 to 4, or the vector of claim 5 or claim 6, and the expression of said nucleic acid or vector in a plant.

15 11. A method according to claim 10 wherein said plant allows posttranslational modifications and/or overproduction of said immunoglobulin proteins.

12. A method according to claim 10 or claim 11 wherein post-translational modifications of the antibodies are carried out in the plant *in vivo*.

20 13. A method according to claim 10 or claim 11 wherein post-translational modifications of the antibodies are carried out *in vitro*.

25 14. A method for selecting plants producing antibodies that bind to a specific protein, or fragment thereof, comprising the following steps:

(a) purify recombinant antibodies from a pool of plants expressing said antibodies;

(b) assay said antibodies to determine whether any bind to the specific protein or fragment thereof;

5 (c) and if the results of step (b) are positive, repeating steps (a) and (b) with the pool of plants sub divided into smaller groups; and

(d) repeating steps (a) to (c) until the plant producing the antibody that binds the specific protein or fragment thereof is identified.

10 15. The method as claimed in claim 14 wherein the initial pool contains 1000 plants, which is subdivided by a factor of ten in step (c).

16. The method as claimed in claim 14 or claim 15 wherein the assay of step (b) is carried out by means of ELISA.

15 17. The method as claimed in any one of claims 14 to 16 wherein the specific protein is a viral protein.

20 18. The method as claimed in claim 17 wherein the protein is an HIV virus protein.

19. The method as claimed in claim 18 wherein said protein is an HIV-1 envelope protein.

25 20. A pharmaceutical composition comprising an antibody identified by the method as claimed in any one of claims 14 to 19.

21. The use of a nucleic acid molecule as claimed in any one of claims 1 to 4, or a vector as claimed in claim 5 or 6 in the production of a transgenic plant.

Figure 2

5




Figure 4






Figure 3

100 plant extracts
per well



10 plant extracts
per well



1 plant extract
per well





Figure 1



PCT Application
IB0304056



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.